150 related articles for article (PubMed ID: 17602267)
1. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.
Hathurusinghe HR; Goonetilleke KS; Siriwardena AK
Ann Surg Oncol; 2007 Oct; 14(10):2714-20. PubMed ID: 17602267
[TBL] [Abstract][Full Text] [Related]
2. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer].
Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS
Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575
[TBL] [Abstract][Full Text] [Related]
4. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
5. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
Hardt PD; Ewald N
Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.
Bandara IA; Baltatzis M; Sanyal S; Siriwardena AK
World J Surg Oncol; 2018 Mar; 16(1):56. PubMed ID: 29540198
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
9. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
10. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
11. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
12. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
13. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
14. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
15. Plasma Tumor M2-Pyruvate Kinase Levels in Different Cancer Types.
Muñoz-Colmenero A; Fernández-Suárez A; Fatela-Cantillo D; Ocaña-Pérez E; Domínguez-Jiménez JL; Díaz-Iglesias JM
Anticancer Res; 2015 Jul; 35(7):4271-6. PubMed ID: 26124389
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapy.
Hoopmann M; Warm M; Mallmann P; Thomas A; Göhring UJ; Schöndorf T
Cancer Lett; 2002 Dec; 187(1-2):223-8. PubMed ID: 12359372
[TBL] [Abstract][Full Text] [Related]
17. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.
Fatela-Cantillo D; Fernandez-Suarez A; Moreno MA; Gutierrez JJ; Iglesias JM
Tumour Biol; 2012 Jun; 33(3):825-32. PubMed ID: 22231432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]